Use of cyclophilin D inhibitors to treat or prevent bone disorders
Provided herein are methods of treating or preventing a bone disorder in a subject.
1. A method of treating or preventing a bone disorder in a subject, comprising administering to a subject with or at risk of developing a bone disorder an effective amount of a cyclophilin D inhibitor, wherein the bone disorder is a bone disorder associated with decreased osteogenesis, and wherein the bone disorder is osteoporosis or osteoarthritis.
2. The method of claim 1 , wherein the cyclophilin D inhibitor is selected from the group consisting of N-methyl-4-isoleucine cyclosporin (NIM811), Debio 025, Sanglifehrin A, cyclosporin A and GW5.
3. The method of claim 1 , wherein administration of the cyclophilin D inhibitor increases osteogenicity of mesenchymal stem cells in the subject.
4. The method of claim 1 , wherein administration of the cyclophilin D inhibitor increases mitochondrial function in the subject.
5. The method of claim 1 , wherein the cyclophilin D inhibitor is selected from the group consisting of N-methyl-4-isoleucine cyclosporin (NIM811), Debio 025, Sanglifehrin A, cyclosporin A and GW5.